BMO Capital Initiates Coverage On Silence Therapeutics with Outperform Rating, Announces Price Target of $67
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris has initiated coverage on Silence Therapeutics (NASDAQ:SLN) with an Outperform rating and set a price target of $67.
January 31, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has initiated coverage on Silence Therapeutics with an Outperform rating and a price target of $67, indicating a positive outlook for the stock.
The initiation of coverage by BMO Capital with an Outperform rating typically suggests a bullish view on the stock's potential performance. The price target of $67 is a strong indicator of expected positive momentum, which could influence investor sentiment and drive short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100